We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Dr. Fátima Valdés Mora. Head research group Cancer Epigenetic Biology and Therapeutics, Children’s Cancer Institute. Sydney
Abstract: Diffuse midline glioma (DMG) is the most aggressive brain tumour in children, with a median survival of less than one year and with no cure. DMG is an epigenetically driven cancer, where more than 85% of the cases are characterised by a global loss of the repressive epigenetic mark, histone 3 trimethylation at the lysine 27 (H3K27me3). This is caused by a single somatic mutation in the histone H3, called H3K27M, or by the overexpression of the developmental gene EZHIP, a natural mimic of H3K27M, and subclassifies these DMGs as “H3K27-altered”. Unfortunately, the epigenomic landscape of H3K27-altered DMG is far from been completed and thus epigenetic therapies tested in DMG to date have not been rationalized based on such information. Valdes Mora group’s mission is to complete the epigenomic landscapes on H3K27-altered DMGs, not only in the cancer cells but also in the cells from the tumour microenvironment (TME). Ultimately, we aim to use research-informed epigenetic therapy to target both the cancer cells and the cells from the TME as a novel therapeutic strategy for H3K27-altered DMG.
Host: Dr. Aroa Soriano Fernández. Main researcher. Childhood Cancer and Blood Disorders (VHIR)
enllaç online:
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.